Boston Scientific Corporation $BSX Stock Holdings Raised by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its stake in Boston Scientific Corporation (NYSE:BSX) by 47.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,306,176 shares of the medical equipment provider’s stock after purchasing an additional 1,391,559 shares during the quarter. Boston Scientific makes up approximately 0.6% of Assenagon Asset Management S.A.’s holdings, making the stock its 27th biggest holding. Assenagon Asset Management S.A. owned about 0.29% of Boston Scientific worth $410,594,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BSX. Brighton Jones LLC grew its position in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Magnetar Financial LLC lifted its stake in Boston Scientific by 15.9% during the second quarter. Magnetar Financial LLC now owns 5,782 shares of the medical equipment provider’s stock worth $621,000 after purchasing an additional 794 shares during the last quarter. Hillsdale Investment Management Inc. boosted its holdings in Boston Scientific by 14.9% in the second quarter. Hillsdale Investment Management Inc. now owns 6,950 shares of the medical equipment provider’s stock worth $746,000 after purchasing an additional 900 shares during the period. AlphaCore Capital LLC acquired a new position in Boston Scientific in the second quarter worth $261,000. Finally, Segall Bryant & Hamill LLC increased its stake in Boston Scientific by 15.3% during the second quarter. Segall Bryant & Hamill LLC now owns 94,097 shares of the medical equipment provider’s stock valued at $10,107,000 after purchasing an additional 12,477 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

NYSE BSX opened at $69.54 on Tuesday. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50. The firm has a market capitalization of $103.34 billion, a PE ratio of 35.84, a P/E/G ratio of 0.97 and a beta of 0.69. The company’s 50 day simple moving average is $79.22 and its 200 day simple moving average is $91.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham & Company reiterated a “Buy” rating on BSX, reinforcing institutional support for the shares amid the post-earnings pullback; this helps underpin demand from investors looking for growth exposure in medical devices. Boston Scientific’s (BSX) “Buy” Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Several market write-ups argue the pullback could be a buying opportunity given solid recent fundamentals (beat on adjusted EPS, strong free cash flow, growth in EP and Watchman) and potential catalysts such as Champion-AF trial results and the planned Penumbra acquisition — but these are contingent on upcoming clinical and integration outcomes. Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback?
• Negative Sentiment: Multiple law firms have filed or are soliciting clients for a securities class action covering purchases between July 23, 2025 and Feb 3, 2026; they remind investors of a May 4, 2026 lead-plaintiff deadline — this increases legal overhang and potential litigation costs/settlement risk. ROSEN – Class Action Notice Robbins LLP – Class Action Alert Faruqi & Faruqi – Class Action Notice
• Negative Sentiment: MassDevice reports alleged long-running pacemaker battery problems — product reliability and potential recalls or regulatory scrutiny could materially affect device sales and margins if issues are confirmed and widespread. Boston Scientific has reportedly had pacemaker battery problems for years
• Negative Sentiment: Stifel cut its price target on BSX to $90, signaling some analyst caution and reduced near-term upside expectations even where ratings remain constructive — this can weigh on sentiment and caps potential rebound momentum. Stifel Nicolaus Cuts Boston Scientific Price Target to $90

Analyst Upgrades and Downgrades

BSX has been the topic of a number of recent research reports. Mizuho reduced their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $97.00 price objective on shares of Boston Scientific in a research report on Friday. Truist Financial dropped their price objective on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Jefferies Financial Group reissued a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. Finally, Canaccord Genuity Group decreased their target price on Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $106.27.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.